ObesityWeek 2026 Exhibitors
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
111 organizations exhibit at ObesityWeek 2026 — 71 suppliers and service companies, 21 drug developers, 13 government bodies and non-profits, 4 hospitals and clinics and 2 universities and research institutes. 33 of them also present on the scientific program, with 125 presentations between them. Most represented: Eli Lilly, Novo Nordisk and Cleveland Clinic. As of Nov 12, 2026.
Topic
Top represented
Showing 1–30 of 111 organizations
| Organization | ObesityWeek 2026 Attendance |
|---|---|
Eli Lilly Indianapolis, IN | ◆Platinum Sponsor |
Global medicine company working in diabetes, obesity and its long-term complications, Alzheimer's disease, immune disorders and hard-to-treat cancers. | Booth Exhibiting at Booth 509, 900, Suite 4, Suite 11, Suite 12, Suite 19, Suite 19a, Suite 19b, Suite 19c, Suite 19d, Suite 19e, Suite 27 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sat Nov 14 12:00pm–1:00pm Women Inspiring and Elevating Leadership in Diabetes (WIELD): Pearls of Wisdom from Obesity Trailblazers Across Career Stages and Fields Women leaders from academia and industry share career-building strategies for trainees and established investigators, with time to network. Poster Sat Nov 14 7:30pm–8:30pm Eloralintide Added to Established Tirzepatide Enhanced Weight and Fat Loss in DIO Rats Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Significant Increases in SHBG Accompanying Weight Loss with Tirzepatide in the SURMOUNT Program Chronic disease and obesity complicationsMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Two-year HbA1c and Weight Outcomes by Tirzepatide Persistence Pattern in Type 2 Diabetes Metabolism and integrative physiology Talk Sun Nov 15 7:30am–8:30am Weight Management Foundayo Peer-led review of dosing, efficacy and safety for a once-daily oral obesity medicine for adults, with time for audience questions. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and food Poster Sun Nov 15 2:30pm–3:30pm Weight-Loss Targets for Predicting Glucose Normalization: SURMOUNT-1 176-Week Post-Hoc Analysis Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Patients Reported Orforglipron Was Simple, Convenient, Easy to Use: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Reasons for Orforglipron Initiation and Treatment Goals: Results from the FOUNDERS Survey Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Phase 2 Study of Tirzepatide Plus Mibavademab Compared with Tirzepatide Alone in Adults With Obesity Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Loss with 18-Month Tirzepatide Use in Adults with Obesity and without Diabetes Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Healthcare Costs Trends with Tirzepatide Use in Treatment of Obesity: A Matched Cohort Analysis Obesity pharmacotherapy and drug developmentPolicy and public health Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes Among Zepbound (Tirzepatide) Users Engaging with the Lilly Health App Obesity pharmacotherapy and drug developmentInterventional and clinical studies Talk Sun Nov 15 3:30pm–3:45pm Talk Sun Nov 15 6:30pm–8:00pm One Patient, Many Perspectives: A Multidisciplinary Expert Roundtable on Obesity Care Specialists from primary care, cardiology, sleep medicine, surgery and other fields discuss one shared patient case to show how coordinated obesity care works. Metabolism and integrative physiologyInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceChronic disease and obesity complications Talk Mon Nov 16 7:00am–8:30am Beyond the Airway: Metabolic Drivers of Obstructive Sleep Apnea Small-group work through patient cases on how excess body fat contributes to obstructive sleep apnea, and on screening, diagnosis and treatment choices. Chronic disease and obesity complications Talk Mon Nov 16 7:15am–8:15am Seen Beyond the Scale: Addressing Weight Bias and Stigma in Pediatric Obesity Care Looks at how weight bias and stigma show up in pediatric care and gives clinicians ways to talk about weight respectfully with families. Pediatric and adolescent obesityClinical obesity care and professional practicePolicy and public health Talk Mon Nov 16 8:45am–9:00am Talk Mon Nov 16 11:45am–1:15pm Discover Zepbound (Tirzepatide) Injection Reviews efficacy, safety and dosing evidence for tirzepatide injection and how to identify adult patients who may be suitable for it. Metabolism and integrative physiologyPopulation health and epidemiologyNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 1:30pm–1:45pm Focus on Transitioning from Academia to Industry as Early Career Researcher Metabolism and integrative physiologyNeuroscience of appetite and eatingInterventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Achieving Clinical Goals with Tirzepatide Treatment in the SURMOUNT-MAINTAIN Trial: A Post-hoc Analysis Pediatric and adolescent obesityObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm Poster Mon Nov 16 2:30pm–3:30pm |
Novo Nordisk Bagsværd, Denmark | ◆Platinum Sponsor |
Global healthcare company with a century of diabetes medicines, also treating obesity and rare blood and endocrine disorders, with its US arm in New Jersey. | Booth Exhibiting at Booth 309, 715, Suite 7, Suite 7a, Suite 7b Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin Explores obesity-related inflammation, how current drugs affect it, and evidence for emerging amylin-based therapies, including combined GLP-1 and amylin drugs. Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm Real-World Weight Outcomes with Semaglutide 1.0, 1.7, and 2.4 mg in the US and UK (STEP ADAPT Real) Chronic disease and obesity complications Talk Sun Nov 15 9:45am–10:15am Evidence Snapshot: Addressing Weight and CV Risk in Patients with Obesity Reviews cardiovascular outcomes and chronic weight-management trial data in adults with overweight or obesity, with dosing and administration considerations. Interventional and clinical studiesClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications Poster Sun Nov 15 2:30pm–3:30pm Cagrilintide’s Potential Benefits on Bone Health via Proteomics in Adults With Over-Weight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm AWS Cloud–First Data Discovery for Pragmatic Clinical Trial Linkage Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Preferences for Obesity Medications Among Health Care Professionals Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Obesity Medication Preferences Among Younger and Older Adults: An Age-Stratified Analysis Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Real-World Weight Outcomes and Patient Experience with Oral Semaglutide in a Digital Support Cohort Interventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm 3-Month Food Noise and Patient-Reported Outcomes with Oral Semaglutide for Overweight or Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies Poster Sun Nov 15 2:30pm–3:30pm Characteristics of Early Initiators of Oral Semaglutide for Overweight or Obesity via Telehealth Obesity pharmacotherapy and drug developmentPolicy and public health Talk Sun Nov 15 6:30pm–9:00pm Obesity in Focus: Today's Evidence. Tomorrow's Possibilities. Speakers cover what has changed in obesity guidelines, evidence behind approved obesity drugs, and the biology of amylin and new amylin analog data. Interventional and clinical studiesClinical obesity care and professional practiceNutrition, diet and foodObesity pharmacotherapy and drug development Talk Mon Nov 16 11:30am–1:15pm The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice Case-based discussion of treating obesity as a lifelong chronic disease, with personalized drug choice, combination therapy and continued treatment. Clinical obesity care and professional practiceObesity pharmacotherapy and drug development Poster Mon Nov 16 2:30pm–3:30pm The Predicted Impact of CagriSema on Cardiovascular Disease in US Adults With Overweight or Obesity Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Changes in Purchasing Behavior Following Initiation of GLP-1RAs: Data from a UK Consumer Panel Population health and epidemiologyNutrition, diet and food Poster Mon Nov 16 2:30pm–3:30pm Talk Mon Nov 16 5:00pm–5:15pm |
Cleveland Clinic Cleveland, OH | |
Academic health system in Cleveland uniting patient care, research and education; it exhibits to recruit physicians. | Booth Exhibiting at Booth 738 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 4:30pm–4:45pm What’s New in Bariatric Surgery - And Why It Matters Clinically Clinical obesity care and professional practiceBariatric surgery and devicesObesity pharmacotherapy and drug development Talk Sat Nov 14 4:45pm–5:00pm Talk Sat Nov 14 5:00pm–5:15pm Poster Sat Nov 14 7:30pm–8:30pm Weight Trajectories in Type 2 Diabetes: Glucose-Lowering Therapy and Clinical Outcomes Neuroscience of appetite and eatingObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Clinician Perceptions of Semaglutide and Tirzepatide & Alternative Therapies Considered for Obesity Clinical obesity care and professional practice Poster Sun Nov 15 2:30pm–3:30pm Asymmetric Re-Titration After Discontinuation of GLP-1 and GLP-1/GIP Receptor Agonists: Dose Patterns Differ Between Obesity and Type 2 Diabetes Clinical obesity care and professional practice Session Mon Nov 16 8:30am–9:30am TOS/ASMBS Joint Symposium: Horizons in Collaborative Obesity Treatment Experts survey new obesity treatments, from next-generation drugs to combined approaches, and how medical and surgical teams can work together. Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentBariatric surgery and devices Talk Mon Nov 16 8:45am–9:00am Published and Real World Evidence of Anti-Obesity Medications and Metabolic and Bariatric Surgery Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentBariatric surgery and devices Session Mon Nov 16 12:00pm–1:00pm TOS Clinical Practice Section Meeting (TOS members only) - Obesity Medicine in 2031: What Will It Look Like? A multidisciplinary panel looks ahead to obesity care in 2031, then the section recognizes its clinician and practitioner awards for obesity care. Clinical obesity care and professional practice Session Mon Nov 16 5:00pm–6:30pm The Hidden Burden of Trauma in Obesity: What Health Care Professionals Need to Know Explains how trauma can shape weight, treatment engagement and outcomes, and offers trauma-informed ways to build trust and reduce stigma in care. Clinical obesity care and professional practiceBariatric surgery and devicesNutrition, diet and food |
Obesity Action Coalition Tampa, FL | |
Nonprofit that speaks for people living with obesity and supports them with advocacy, education and community. | Booth Exhibiting at Booth 337 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Fri Nov 13 1:00pm–6:15pm Pediatric Obesity: Comprehensive Care and Practical Strategies for Today's Clinician - Day 1 Practical course for clinicians on pediatric obesity care, combining nutrition, behavior therapy and newer drugs, with case simulations and workflow strategies. Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentPediatric and adolescent obesityNutrition, diet and food Session Sat Nov 14 8:00am–12:45pm Pediatric Obesity: Comprehensive Care and Practical Strategies for Today's Clinician - Day 2 Interprofessional course on pediatric obesity care, covering nutrition counseling, behavior therapy, newer medicines, special populations and clinic efficiency. Clinical obesity care and professional practiceObesity pharmacotherapy and drug developmentPediatric and adolescent obesityNutrition, diet and food Session Sat Nov 14 1:30pm–2:30pm The Evolving Plate: How Nutritional Needs Shift Throughout the Obesity Care Journey Shows how care teams can track nutrition status and micronutrient needs throughout obesity treatment, since many patients start with existing nutrient gaps. Clinical obesity care and professional practiceNutrition, diet and food Talk Sun Nov 15 9:00am–9:15am Session Sun Nov 15 9:30am–10:30am Session Sun Nov 15 6:00pm–8:00pm Talk Mon Nov 16 11:45am–12:45pm Glucagon’s Role in Metabolic Regulation and Why It Matters Covers how glucagon and the liver regulate glucose and fat metabolism and why this matters in obesity and related heart, kidney and metabolic diseases. Metabolism and integrative physiologyChronic disease and obesity complications Talk Tue Nov 17 8:30am–8:40am Patient Perspective Clinical obesity care and professional practice |
AdventHealth Research Institute Orlando, FL | |
Research arm of the AdventHealth system, including its Translational Research Institute studying obesity, diabetes and metabolism. | Booth Exhibiting at Booth 443 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 3:00pm–3:25pm Human Brain Scans with Metabolic Disease Revealing Risk for Neurodegeneration Metabolism and integrative physiologyNeuroscience of appetite and eating Talk Mon Nov 16 2:15pm–2:30pm Talk Mon Nov 16 5:00pm–5:25pm Fat Where It Doesn't Belong: Cellular Heterogeneity and Cardiometabolic Relevance of Intermuscular Adipose Tissue Metabolism and integrative physiologyNutrition, diet and foodObesity pharmacotherapy and drug development Talk Tue Nov 17 9:00am–9:15am Talk Tue Nov 17 9:15am–9:30am |
Pfizer New York, NY | ◇Bronze Sponsor |
Global drugmaker that discovers, develops and manufactures medicines and vaccines across many diseases. | Booth Exhibiting at Booth 601, Suite 20, Suite 20a, Suite 21, Suite 21a Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm NAD+ Augmentation via Nicotinamide Riboside Does Not Improve Cardiorespiratory Fitness in Aged Mice Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Monthly Berobenatide in Adults with Obesity/Overweight: VESPER-3 Cardiometabolic Risk Markers Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm A Multi‑omics View of Skeletal Muscle Responses to GLP‑1R Agonism in Obese Mice Metabolism and integrative physiology Poster Sun Nov 15 2:30pm–3:30pm Effects of a Potent and Selective Small Molecule GIPR Antagonist in Preclinical Models of Obesity Interventional and clinical studies Poster Mon Nov 16 2:30pm–3:30pm Human-AI Co-Developed Algorithms for CGM-Based Meal Detection: New Paradigm for Digital Endpoints Nutrition, diet and foodPopulation health and epidemiology |
Wave Life Sciences Cambridge, MA | ◇Bronze Sponsor |
RNA medicines company whose pipeline includes WVE-007 for obesity, plus programs in alpha-1 antitrypsin deficiency and PNPLA3-linked liver disease. | Booth Exhibiting at Booth 428 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 11:45am–1:15pm Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of? Asks whether body composition, not weight loss alone, should measure obesity treatment success, and reviews activin E biology and small interfering RNA drugs. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 11:55am–12:10pm Changing the Treatment Paradigm in Overweight and Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:10pm–12:35pm Beyond The Scale: The Clinical Relevance of Body Composition, Body Fat Distribution and Lean Mass Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 12:35pm–1:00pm From Genetic Evidence to Therapeutic Hypothesis: the INHBE-Activin E Pathway as a Target for Obesity Management Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 1:10pm–1:15pm Rethinking Success: Where Should Obesity Treatment Go? Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practiceMetabolism and integrative physiologyObesity pharmacotherapy and drug development Talk Sat Nov 14 4:30pm–4:45pm Poster Sun Nov 15 2:30pm–3:30pm Interim Data From INLIGHT: A Phase 1 Study of WVE-007 in Adults Living With Overweight and Obesity Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Amgen Thousand Oaks, CA | ◆Silver Sponsor |
Biotechnology company drawing on biology, technology and human genetic data to develop medicines for serious diseases. | Booth Exhibiting at Booth 501, Suite 22, Suite 23 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm Brain Activation Profiling and Tissue-Based Omics in Mice Exposed to GIPR Antagonism Versus Agonism Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology Talk Sun Nov 15 7:30am–8:30am The Obesity Treatment Journey: Evaluating Burden, Discontinuation, and Outcomes Uses a patient case and real-world data to examine why patients stop obesity treatment, what follows, and care changes that keep people on therapy. Interventional and clinical studiesPopulation health and epidemiologyClinical obesity care and professional practicePolicy and public healthNutrition, diet and foodChronic disease and obesity complicationsNeuroscience of appetite and eatingObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Medical Cost and Use by GLP-1 RA Persistence Status in US Patients With Obesity/Overweight Clinical obesity care and professional practice Poster Mon Nov 16 2:30pm–3:30pm Correlation of BMI With Central Adiposity and Body Composition Measures in UK Biobank Population health and epidemiology |
Boehringer Ingelheim Ingelheim, Germany | ◆Gold Sponsor |
Family-owned pharmaceutical company developing treatments for obesity and MASH, including the glucagon and GLP-1 dual agonist survodutide. | Booth Exhibiting at Booth 221, Suite 24, Suite 25 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sat Nov 14 3:30pm–3:45pm Poster Sat Nov 14 7:30pm–8:30pm Psychometric Validation of the Eating Behavior Patient-Reported Outcome Measure in Japan Nutrition, diet and food Poster Sat Nov 14 7:30pm–8:30pm Content Validation of the Eating Behavior Patient-Reported Outcome Measure in Japan Nutrition, diet and food Poster Sat Nov 14 7:30pm–8:30pm Talk Sun Nov 15 11:45am–1:15pm Bridging Obesity and MASLD Through Metabolic Dysfunction Links obesity, visceral and liver fat, and MASLD, making the case for waist measures and early liver checks, with patients describing their own experience. Metabolism and integrative physiologyChronic disease and obesity complications Poster Sun Nov 15 2:30pm–3:30pm Behavioral Phenotyping in Obesity Management: Insights from the Survodutide SYNCHRONIZE™-1 Trial Obesity pharmacotherapy and drug developmentInterventional and clinical studies Talk Sun Nov 15 6:30pm–8:30pm Clinical Case Files: Following the Metabolic Clues in Obesity and MASLD Case-based problem-solving on spotting MASLD risk early and coordinating liver and metabolic care for patients with obesity. Metabolism and integrative physiologyClinical obesity care and professional practiceObesity pharmacotherapy and drug developmentChronic disease and obesity complications Talk Mon Nov 16 11:45am–12:45pm Glucagon’s Role in Metabolic Regulation and Why It Matters Covers how glucagon and the liver regulate glucose and fat metabolism and why this matters in obesity and related heart, kidney and metabolic diseases. Metabolism and integrative physiologyChronic disease and obesity complications |
American Academy of Pediatrics Itasca, IL | |
Pediatricians' society whose Institute for Healthy Childhood Weight helps clinicians put obesity and disordered-eating guidance into everyday practice. | Booth Exhibiting at Booth 838 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Mon Nov 16 7:15am–8:15am Seen Beyond the Scale: Addressing Weight Bias and Stigma in Pediatric Obesity Care Looks at how weight bias and stigma show up in pediatric care and gives clinicians ways to talk about weight respectfully with families. Pediatric and adolescent obesityClinical obesity care and professional practicePolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Childhood Obesity Treatment and Approach: Is Practice Capacity Associated With Quality Improvement? Pediatric and adolescent obesityPopulation health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Improvements in Capacity for Implementing Intensive Health Behavior and Lifestyle Treatment in Variable Pediatric Care Settings Pediatric and adolescent obesity |
Dexcom San Diego, CA | |
Maker of continuous glucose monitoring systems that people use to manage diabetes and track their glucose. | Booth Exhibiting at Booth 709 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm 18-Month Weight Outcomes with Dexcom G7 CGM in Non-Insulin–Treated T2D: US Primary Care Registry Chronic disease and obesity complicationsObesity pharmacotherapy and drug development Poster Sat Nov 14 7:30pm–8:30pm BMI Differences in Psychosocial and Behavior Outcomes After CGM Use in Adults With Type 2 Diabetes Chronic disease and obesity complicationsMetabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Combined Effect of RT-CGM and Tirzepatide on HbA1c and BMI Change in Type 2 Diabetes not on Insulin Metabolism and integrative physiology |
George Mason University Fairfax, VA | |
Virginia public university whose Department of Nutrition and Food Studies trains students in dietetics, community nutrition, research and food access. | Booth Exhibiting at Booth 131 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Dieting, Dietary Restraint, Emotional Status & Long-Covid Symptoms: Relationship to Food Noise & Weight Change Obesity pharmacotherapy and drug developmentPolicy and public health Poster Mon Nov 16 2:30pm–3:30pm Behavioral, Psychosocial, and Body Composition Changes During the Holidays Among College Students Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Nutrition Education in Pre-Schoolers: Findings from the Fresh Food Explorers Observational Study Population health and epidemiology |
Private foundation funding research to define, diagnose and treat lipedema, spanning physiology, genomics, immunology and endocrinology. | Booth Exhibiting at Booth 339 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Mon Nov 16 3:30pm–4:30pm TOS/LF Collaborative Symposium: Lipedema: Rethinking Obesity Care and Research Explains why lipedema, a condition whose diagnosis can take decades, is often missed in obesity care and how clinicians and researchers can address it. Clinical obesity care and professional practiceChronic disease and obesity complicationsMetabolism and integrative physiology Talk Mon Nov 16 3:30pm–3:45pm Living With Lipedema: A Patient Perspective on Diagnosis, Care and Research Impact Clinical obesity care and professional practiceChronic disease and obesity complicationsMetabolism and integrative physiology Talk Mon Nov 16 3:45pm–4:00pm Mapping the Future of Lipedema Science Clinical obesity care and professional practiceChronic disease and obesity complicationsMetabolism and integrative physiology |
Parexel Durham, NC | |
Global contract research organization that designs and runs clinical trials for drug developers, with regulatory and consulting services. | Booth Exhibiting at Booth 115 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Operational Excellence in Early-Phase Obesity Trials: Protocol, Retention, and Timeline Insights Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Healthy Obese is Not a Traditional Healthy Volunteer: Considerations in Early Obesity Drug Trials Interventional and clinical studiesObesity pharmacotherapy and drug development Poster Sun Nov 15 2:30pm–3:30pm Vision-Threatening Ocular Safety of GLP-1 Receptor Agonists: A Propensity-Matched Study Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
◇Bronze Sponsor | |
Clinical-stage biotech building a portfolio of obesity medicines meant to give patients options at each stage of treatment. | Booth Exhibiting at Booth Suite 17 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm Natural History & Real-World Effectiveness of Obesity Management Medications: REFLECT Design/Methods Population health and epidemiology Poster Mon Nov 16 2:30pm–3:30pm Quantifying the Clinical Unmet Need in Adults With Class II and III Obesity in the United States Population health and epidemiologyNutrition, diet and food |
WuXi AppTec Shanghai, China | |
Contract research, development and manufacturing company whose preclinical services include mouse models of obesity and metabolic liver disease for drug testing. | Booth Exhibiting at Booth 123 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm SiRNA‑Mediated ALK7 Knockdown Improves Metabolic Response to Tirzepatide and Preserves Lean Mass Metabolism and integrative physiology Poster Sat Nov 14 7:30pm–8:30pm Novel High‑Fat Diets Rapidly Produce Next‑Generation Mouse Models of Metabolic Dysfunction-Associated Steatohepatitis Metabolism and integrative physiology |
Amylyx Pharmaceuticals Cambridge, MA | ◇Bronze Sponsor |
Develops investigational therapies for endocrine and neurodegenerative conditions, including treatment for hypoglycemia after bariatric surgery. | Booth Exhibiting at Booth 701, Suite 1 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sun Nov 15 5:30pm–8:00pm Session Mon Nov 16 7:30am–8:30am Poster Mon Nov 16 2:30pm–3:30pm Identification of Individuals With Post-Bariatric Hypoglycemia in US Claims Data: Insights and Opportunities Population health and epidemiology |
Gerontological Society of America Washington, DC | |
Interdisciplinary aging-research society of researchers, educators and clinicians; publishes the KAER toolkit for managing obesity in older adults. | Booth Exhibiting at Booth 537 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Mon Nov 16 1:30pm–2:30pm TOS/EASO/GSA Symposium: Bridging Science and Practice for Older Adults - Integrating the 2026 EASO Staging Framework and GSA KAER Toolkit Applies a 2026 European staging framework and a gerontology toolkit to obesity care for older adults, putting muscle, bone and independence before weight loss. Clinical obesity care and professional practice Talk Mon Nov 16 2:00pm–2:15pm The KAER Toolkit in Action: Multimodal Management and Community Connectivity Clinical obesity care and professional practice |
Rhythm Pharmaceuticals Boston, MA | ◆Silver Sponsor |
Biopharmaceutical company developing precision medicines for rare neuroendocrine diseases, including acquired hypothalamic obesity. | Booth Exhibiting at Booth 401 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Sun Nov 15 12:00pm–1:00pm Defining Acquired Hypothalamic Obesity: An International Expert Consensus on Diagnostic Criteria in Children and Adults Unveils 2026 international consensus criteria for diagnosing acquired hypothalamic obesity, a rare form caused by hypothalamic damage, in children and adults. Policy and public health Talk Mon Nov 16 7:30am–8:30am The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity Case-based guide to spotting obesity caused by hypothalamic damage from tumors, brain injury or stroke, with Phase 3 results for a targeted drug. Clinical obesity care and professional practicePediatric and adolescent obesityObesity pharmacotherapy and drug developmentNeuroscience of appetite and eatingInterventional and clinical studies |
AstraZeneca Cambridge, UK | |
Its cardiovascular, renal and metabolism unit develops medicines that slow disease and protect the heart, kidneys, liver and pancreas. | Booth Exhibiting at Booth 301 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm AZD9550, a Dual GLP-1R/GCGR Agonist, Improves Hepatic Steatosis in Wild-Type and GLP-1R Knock-Out Mice on a MASH Diet Chronic disease and obesity complicationsMetabolism and integrative physiology |
Preclinical research company offering human adipose tissue models, efficacy screening and a biobank of adipose tissue and cells. | Booth Exhibiting at Booth 329 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm A Functional 3D Model of Human Adipose Lobule Combining Adipocyte Progenitors and Mature Adipocytes Chronic disease and obesity complicationsObesity pharmacotherapy and drug development |
US clinical research company with 20+ owned sites running obesity and metabolic trials from first-in-human to Phase 3, plus metabolic assessments. | Booth Exhibiting at Booth 203 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Treatment Discontinuation and Weight Regain Bias Treatment Effect Estimates in Obesity Trials Obesity pharmacotherapy and drug developmentInterventional and clinical studies |
Telemedicine obesity-medicine clinic where physician-led teams with dietitians deliver multidisciplinary, evidence-based weight treatment. | Booth Exhibiting at Booth 110 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sun Nov 15 2:30pm–3:30pm Virtual Shared Medical Appointments in Obesity Care Are Associated With High Patient Satisfaction Clinical obesity care and professional practiceObesity pharmacotherapy and drug development |
Genentech South San Francisco, CA | ◇Bronze Sponsor |
Roche Group biotechnology company that discovers, develops and markets medicines for serious diseases. | Booth Exhibiting at Booth 330, Suite 26 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm Petrelintide Co-Administered With Enicepatide in People Living With Obesity or Overweight (ZYNERGY) Chronic disease and obesity complications |
Syneos Health Morrisville, NC | |
Biopharmaceutical services company combining clinical research with commercialization support, informed by patient, physician and real-world insights. | Booth Exhibiting at Booth 300, Suite 5b Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm Uncovering Barriers to Therapy Adoption by Patient GLP-1 Use Status: A Cross-Sectional Analysis Using an AI-Enabled Patient Priority Tool Clinical obesity care and professional practice |
Clinical research company linking consented patients and their health records to registries, trial recruitment and decentralized studies, including a cardiometabolic disease registry. | Booth Exhibiting at Booth 846 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Mon Nov 16 2:30pm–3:30pm |
Certifies physicians in obesity medicine through assessment and credentialing, with more than 11,600 diplomates across the US and Canada. | Booth Exhibiting at Booth Suite 13 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Sun Nov 15 4:30pm–6:00pm |
◇Bronze Sponsor | |
Pharmaceutical company, now home to Currax's products, selling over 50 medicines in ten therapeutic areas. | Booth Exhibiting at Booth 220 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Talk Mon Nov 16 11:30am–1:15pm The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice Case-based discussion of treating obesity as a lifelong chronic disease, with personalized drug choice, combination therapy and continued treatment. Clinical obesity care and professional practiceObesity pharmacotherapy and drug development |
Federation of national obesity associations from 40 European countries working on obesity science, policy, prevention and care. | Booth Exhibiting at Booth 545 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Mon Nov 16 1:30pm–2:30pm TOS/EASO/GSA Symposium: Bridging Science and Practice for Older Adults - Integrating the 2026 EASO Staging Framework and GSA KAER Toolkit Applies a 2026 European staging framework and a gerontology toolkit to obesity care for older adults, putting muscle, bone and independence before weight loss. Clinical obesity care and professional practice |
Partnership of CDC, NIH, USDA and the Robert Wood Johnson Foundation that coordinates funding and research to reduce childhood obesity. | Booth Exhibiting at Booth 842 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Session Mon Nov 16 10:00am–11:30am TOS/NCCOR Collaborative Symposium: Assessing Capacity to Address Obesity Using Whole-of-Systems Approaches for Cancer Prevention and Control Shares lessons from community projects that use policy, systems and environmental changes to prevent obesity, with an eye to cancer prevention. Population health and epidemiologyChronic disease and obesity complications |
Find buyers from ObesityWeek 2026 exhibitors
Tell us what you sell and we’ll find the people at these exhibitors most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Browse ObesityWeek 2026 by
Organization type
Topic
- Obesity pharmacotherapy and drug development 251
- Clinical obesity care and professional practice 196
- Interventional and clinical studies 231
- Metabolism and integrative physiology 217
- Nutrition, diet and food 164
- Pediatric and adolescent obesity 117
- Population health and epidemiology 156
- Chronic disease and obesity complications 224
- Neuroscience of appetite and eating 97
- Bariatric surgery and devices 58
- Policy and public health 102
Exhibit hall
- Exhibitors 111
Everyone
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction